Companies › Jubilant Therapeutics
1 active drug program in 2 registered trials: 1 Phase 1, 1 Phase 2; Oncology; next expected readout Jun 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| JBI-802 CoREST inhibitor dual targeting LSD1 and HDAC6 | LSD1, HDAC (class I/II) | Phase 1 | Essential Thrombocythemia (ET); Lung Cancer (NSCLC) | Jun 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07207395 | JBI-802 | Phase 2 | Lung Cancer (NSCLC) | Oncology | Oct 2027 |
| NCT07612280 | JBI-802 | Phase 1 | Essential Thrombocythemia (ET) | Oncology | Jun 2028 |
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.